Abingworth

Tracked participation in 1 Atlas company, with 2 explicitly attributed leads.

1portfolio companies

5round participations

2lead positions

$200Mled round total

Conviction

Most recent leads

The latest rounds this investor is sourced as leading, newest first.

Oct 2023Iambic TherapeuticsSeries B (oversubscribed)$100MOct 2021Iambic TherapeuticsSeries B$100M

Capital activity

Portfolio

CompanyLatest valuationFirst → latestRoundsRoleAttributed partner

ITIambic TherapeuticsScienceIambic Therapeutics (formerly Entos) is a clinical-stage life science and technology company developing…$8.4Mvaluation$476MraisedRecent roundsOversubscribed financing round (company described as >$100M) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +15Series B extension (oversubscribed) · Jun 2024$50M · led by Exor Ventures, Mubadala CapitalSeries B (oversubscribed) · Oct 2023$100M · led by Abingworth, Ascenta CapitalIambic Therapeutics—Oct 2021 → Nov 20255 rounds2 led—

DateCompanyRoundRaisedValuationRoleEvidence

Nov 10, 2025ITIambic TherapeuticsScienceIambic Therapeutics (formerly Entos) is a clinical-stage life science and technology company developing…$8.4Mvaluation$476MraisedRecent roundsOversubscribed financing round (company described as >$100M) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +15Series B extension (oversubscribed) · Jun 2024$50M · led by Exor Ventures, Mubadala CapitalSeries B (oversubscribed) · Oct 2023$100M · led by Abingworth, Ascenta CapitalIambic TherapeuticsOversubscribed financing round (company described as >$100M)$100M—Participant

Source ↗

Jun 18, 2024ITIambic TherapeuticsScienceIambic Therapeutics (formerly Entos) is a clinical-stage life science and technology company developing…$8.4Mvaluation$476MraisedRecent roundsOversubscribed financing round (company described as >$100M) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +15Series B extension (oversubscribed) · Jun 2024$50M · led by Exor Ventures, Mubadala CapitalSeries B (oversubscribed) · Oct 2023$100M · led by Abingworth, Ascenta CapitalIambic TherapeuticsSeries B extension (oversubscribed)$50M—Participant

Source ↗

Oct 03, 2023ITIambic TherapeuticsScienceIambic Therapeutics (formerly Entos) is a clinical-stage life science and technology company developing…$8.4Mvaluation$476MraisedRecent roundsOversubscribed financing round (company described as >$100M) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +15Series B extension (oversubscribed) · Jun 2024$50M · led by Exor Ventures, Mubadala CapitalSeries B (oversubscribed) · Oct 2023$100M · led by Abingworth, Ascenta CapitalIambic TherapeuticsSeries B (oversubscribed)$100M—Lead

Source ↗

Jun 18, 2023ITIambic TherapeuticsScienceIambic Therapeutics (formerly Entos) is a clinical-stage life science and technology company developing…$8.4Mvaluation$476MraisedRecent roundsOversubscribed financing round (company described as >$100M) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +15Series B extension (oversubscribed) · Jun 2024$50M · led by Exor Ventures, Mubadala CapitalSeries B (oversubscribed) · Oct 2023$100M · led by Abingworth, Ascenta CapitalIambic TherapeuticsSeries B Extension$50M—Participant

Source ↗

Oct 03, 2021ITIambic TherapeuticsScienceIambic Therapeutics (formerly Entos) is a clinical-stage life science and technology company developing…$8.4Mvaluation$476MraisedRecent roundsOversubscribed financing round (company described as >$100M) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +15Series B extension (oversubscribed) · Jun 2024$50M · led by Exor Ventures, Mubadala CapitalSeries B (oversubscribed) · Oct 2023$100M · led by Abingworth, Ascenta CapitalIambic TherapeuticsSeries B$100M—Lead

Source ↗

DateCompanyRoundRaisedValuationRoleEvidence

Source ↗